| Dr David M Schalk, MD | |
|
804 Snow Hill Rd, Salisbury, MD 21804-1938 | |
| (410) 546-0300 | |
| (410) 546-8364 |
| Full Name | Dr David M Schalk |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 41 Years |
| Location | 804 Snow Hill Rd, Salisbury, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013973718 | NPI | - | NPPES |
| 287911500 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | D0037068 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Western Maryland Regional Medical Center | Cumberland, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North American Partners In Anesthesia Maryland Llc | 1850283144 | 77 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
| Entity Name | North American Partners In Anesthesia Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093707879 PECOS PAC ID: 1850283144 Enrollment ID: O20040330000405 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
| Entity Name | Capital Care Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710110499 PECOS PAC ID: 7113063710 Enrollment ID: O20091013000442 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
| Entity Name | Cumberland Anesthesia Ams Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033531785 PECOS PAC ID: 4981825056 Enrollment ID: O20141015001480 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
| Entity Name | Anesthesia Dynamics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073001012 PECOS PAC ID: 3779832530 Enrollment ID: O20180828001262 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
| Entity Name | Anesthesia Dynamics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215632542 PECOS PAC ID: 3870959638 Enrollment ID: O20230520000018 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David M Schalk, MD 1006 Marley Manor Dr., Apt. # 204, Salisbury, MD 21804 Ph: (410) 603-7155 | Dr David M Schalk, MD 804 Snow Hill Rd, Salisbury, MD 21804-1938 Ph: (410) 546-0300 |
News Archive
Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.
A Rochester Institute of Technology professor has received a federal award for research that could help in the critical battle to develop new drugs to combat the drastic rise in the number of antibiotic-resistant bacteria.
New NIH guidelines, proposed Thursday, are intended "to prevent financial conflicts of interest among [40,000] researchers who receive federal funding, a move long sought by watchdogs of scientific research concerned about the influence of the drug industry and others," The Washington Post reports.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 6 days ago
Alex L Mah, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-543-7375 | |
Nicholas A Woodford, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 100 East Carroll Street, Salisbury, MD 21801 Phone: 410-543-7375 | |
Dr. Ben Tacheron, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6503 Deer Pointe Dr Ste A, Salisbury, MD 21804 Phone: 855-527-7246 Fax: 866-229-5063 | |
Dr. Supriya Banad Jagannath, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-543-7375 | |
Dr. Conworth L Dayton-jones, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 264 Tilghman Rd, Salisbury, MD 21804 Phone: 410-742-7246 | |
Dr. John J Giustozzi, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-543-7375 |